Clinical trial
A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
NCT00214565 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2004
- Completion date
- October 31, 2006
- Enrollment
- 1,450
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.